Navigation Links
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
Date:6/7/2009

NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment.

In the study, 58% of patients treated with liraglutide 1.8 mg once daily reached and maintained the ADA's blood sugar target of A1C less than 7% versus 37% of patients treated with glimepiride 8 mg once daily.

"The fact that liraglutide continues to effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight," said Dr. Alan Garber, Baylor College of Medicine, Houston, a LEAD(TM) 3 principal study investigator. "Even with available treatments, many type 2 diabetes patients still struggle to control their blood sugar, while losing weight. Liraglutide represents an important advance for these patients."

The LEAD(TM) 3 extension study also documented that treatment with liraglutide leads to early and lasting weight loss. Many currently available diabetes treatments lead to weight gain, a concern for type 2 diabetes patients, most of whom are already overweight. After two years of treatment with 1.8 mg of liraglutide, mean body weight decreased significantly (-2.7 kg) compared to overall weight increase in the glimepiride group (+1.1 kg).

Hypoglycemia is a condition where blood sugar levels become too low. Minor hypoglycemia was more than six times less frequent in the liraglutide treatment groups compared with the glimepiride group.

About LEAD(TM) 3 Extension

The LEAD(TM) 3 Extension compared the efficacy and safety of liraglutide (1.8 mg and 1.2 mg, once daily) to glimepi
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
2. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
3. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
10. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
11. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to inflammation and pain in the human body,s joints such ... causes inflammation of the tissues that surround the joints and ... RA begin slowly, usually just mild pain around the joints ...
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... PORTSMOUTH, N.H., Aug. 4, 2011 Novocure, a ... it has entered into a long-term supply agreement ... engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ... ceramic components used to manufacture the disposable electrodes ...
... Texas, Aug. 4, 2011 Healthpoint Biotherapeutics today ... clinical trial investigating the efficacy of HP802-247 in ... living cell suspension containing keratinocytes and fibroblasts. The ... of two cell concentrations and two dosing frequencies ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 2Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 4
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) --,The more chronic medical conditions ... expectancy may be, a new study claims. ... health issues, scientists at Johns Hopkins Bloomberg School of ... explain why gains in life expectancy are slowing in ... such as diabetes, kidney disease and heart failure is ...
(Date:7/28/2014)... Reinberg HealthDay Reporter MONDAY, ... and heart rhythm irregularities are more likely to get a ... In fact, the study of more than 16,000 people found ... likely to get a pacemaker than those without the memory-robbing ... why folks with dementia are so much more likely to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Parker Waichman LLP, ... fighting to ensure that the heroes of 9/11 are never ... has announced an important deadline. According to a VCF ... with a covered cancer on or before October 12, 2012 ... 2014. First responders and others who were allegedly injured by ...
(Date:7/28/2014)... expecting somethinglike the meal you,ve ordered at a ... rhythms sweep through your brain. , These ... a symphony of cellsboth excitatory and inhibitoryplaying together ... been debated, gamma waves have been associated with ... have been tied to schizophrenia, Alzheimer,s disease, autism, ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... in mice shows promise for possible use in treating Alzheimer's ... study. ,Alzheimer's disease is the most common form of ... speech deterioration, and behavioral changes. The main factor in the ... toxic to the brain. ,Researchers say they have found ...
... steps you take to prevent heart attack may also ... risk factors like high blood pressure and high cholesterol ... and can cause death of brain cells over time. ... designed to slow the progression of mixed dementia, vascular ...
... Researchers say most of the existing drugs on the ... are derived from soil bacteria hence researchers feel that ... miracle drugs.// ,More than 1 million microorganisms ... to a life-saving treatment for some of our deadliest ...
... have identified a protein that essentially blocks HIV replication, ... it is not as effective at stopping HIV, say ... issue of Nature. The team, headed by Joseph Sodroski, ... and Infectious Diseases (NIAID). ,"Identification of this ...
... have optic nerve damage are at increased risk for ... with visual impairment. The participants had their sleep-wakefulness cycles ... with those of 12 young subjects with normal sight. ... more likely to have daytime sleepiness than those with ...
... panoramic X-rays can identify postmenopausal women with low skeletal ... taken for the diagnosis of conditions affecting the teeth ... the mandibular cortical shape and width and refer the ... more than 300 women who had no symptoms of ...
Cached Medicine News:
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... Closed System is a latex-free unisex ... safe, simple catheterization designed to reduce ... It includes a 100% latex-free ... EasyOff tear tab makes it easy ...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: